Key Points
- Pro-Dex CEO Kirk Richard Lee Van, Jr. sold 5,872 shares on May 21 at an average price of $62.81, totaling about $368,820. The sale was made under a pre-arranged Rule 10b5-1 trading plan.
- After the transaction, the CEO still owned 93,835 shares, valued at about $5.89 million, which represented a 5.89% decrease in his position. Pro-Dex stock was also trading up 2.6% around the time of the report.
- Pro-Dex recently posted better-than-expected quarterly results, with EPS of $1.20 versus $0.62 expected and revenue of $19.95 million versus $17.90 million expected. Analysts currently have a Hold consensus rating with an average price target of $70.
Pro-Dex, Inc. (NASDAQ:PDEX - Get Free Report) CEO Kirk Richard Lee Van, Jr. sold 4,128 shares of the firm's stock in a transaction on Friday, May 22nd. The shares were sold at an average price of $62.36, for a total value of $257,422.08. Following the transaction, the chief executive officer owned 89,707 shares in the company, valued at approximately $5,594,128.52. This represents a 4.40% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Pro-Dex Stock Performance
Shares of Pro-Dex stock opened at $65.15 on Wednesday. The firm has a market cap of $207.83 million, a P/E ratio of 18.00 and a beta of -0.12. The company has a current ratio of 3.67, a quick ratio of 2.14 and a debt-to-equity ratio of 0.32. Pro-Dex, Inc. has a 12 month low of $23.47 and a 12 month high of $65.88. The stock's fifty day moving average price is $53.42 and its 200-day moving average price is $44.58.
Pro-Dex (NASDAQ:PDEX - Get Free Report) last announced its quarterly earnings results on Thursday, April 30th. The medical instruments supplier reported $1.20 EPS for the quarter, beating the consensus estimate of $0.62 by $0.58. The firm had revenue of $19.95 million for the quarter, compared to analyst estimates of $17.90 million. Pro-Dex had a return on equity of 22.78% and a net margin of 16.08%. On average, equities research analysts expect that Pro-Dex, Inc. will post 3.16 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Pro-Dex
A number of institutional investors have recently added to or reduced their stakes in the stock. Punch & Associates Investment Management Inc. boosted its position in Pro-Dex by 2.9% during the first quarter. Punch & Associates Investment Management Inc. now owns 61,735 shares of the medical instruments supplier's stock valued at $3,032,000 after purchasing an additional 1,735 shares in the last quarter. Geode Capital Management LLC boosted its position in Pro-Dex by 93.2% during the second quarter. Geode Capital Management LLC now owns 51,668 shares of the medical instruments supplier's stock valued at $2,255,000 after purchasing an additional 24,927 shares in the last quarter. JPMorgan Chase & Co. boosted its position in Pro-Dex by 67.7% during the second quarter. JPMorgan Chase & Co. now owns 35,877 shares of the medical instruments supplier's stock valued at $1,566,000 after purchasing an additional 14,479 shares in the last quarter. Osaic Holdings Inc. boosted its position in Pro-Dex by 44.8% during the fourth quarter. Osaic Holdings Inc. now owns 11,434 shares of the medical instruments supplier's stock valued at $440,000 after purchasing an additional 3,540 shares in the last quarter. Finally, Corsair Capital Management L.P. acquired a new position in Pro-Dex during the 1st quarter valued at about $532,000. Institutional investors own 15.28% of the company's stock.
Wall Street Analysts Forecast Growth
A number of equities research analysts recently weighed in on PDEX shares. Weiss Ratings reaffirmed a "hold (c+)" rating on shares of Pro-Dex in a research report on Friday, May 1st. Ascendiant Capital Markets raised their price objective on Pro-Dex from $56.00 to $70.00 and gave the company a "buy" rating in a research report on Tuesday, May 12th. Finally, Zacks Research raised Pro-Dex to a "hold" rating in a research report on Tuesday, May 19th. One investment analyst has rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $70.00.
View Our Latest Stock Report on Pro-Dex
About Pro-Dex
(
Get Free Report)
Pro-Dex, Inc is a designer and manufacturer of precision drive systems and fluid management products serving the dental, medical, industrial and energy markets. The company specializes in high-speed, brushless micromotors and controllers, as well as pneumatic and fluid control devices, providing both standard and custom-engineered solutions for original equipment manufacturers.
Its product portfolio includes high-speed dental handpieces, turbine systems, rotary and reciprocating micro-drives, along with integrated fluid delivery systems.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
